Last updated
Gilead Sciences: Partnership
Gilead agreed to pay Shanghai-based PepStar Therapeutics US$1.275B upfront for global rights to HCXT-2001, an experimental oral IL-23 receptor inhibitor in Phase I, as a licensing deal that strengthens its IBD pipeline.
Source: BioCentury
- What happened
- Gilead agreed to pay Shanghai-based PepStar Therapeutics US$1.275B upfront for global rights to HCXT-2001, an experimental oral IL-23 receptor inhibitor in Phase I, as a licensing deal that strengthens its IBD pipeline.
- Who
- Gilead Sciences · Biotech & Pharma · China
- When
- 2026-10-26
- Source
- BioCentury
- So what
- Alliances broaden the commercial surface, and the leadership need follows.
The leadership read
Alliances broaden the commercial surface, and the leadership need follows. Gilead Sciences's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Asia, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.
Market context: The wider read — a Talent Market Index of 109 (Hot), up 7.3 month-on-month — shows Asia signal flow rising (+2.7pts).
Gilead Sciences: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 33 tracked companies; 0.1% of MitchelLake's Asia signal flow; 6 tracked across 216 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
Partnership · Asia
Bora Pharmaceuticals →Bora Pharmaceuticals signed partnership with Insilico Medicine for AI drug discovery. Company launched group-wide AI in Manufacturing program (BORA AIM) to improve process efficiency across sites.
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Product Launch · Asia
Biogen →Biogen's monoclonal antibody felzartamab received first global approval in China for second-line multiple myeloma treatment, in combination with lenalidomide and dexamethasone.
Product Launch · Asia
Celltrion →Celltrion achieved record quarterly earnings (1.4 trillion won / $950M in sales, 451.8B won operating profit) driven by growing sales of newer biosimilar portfolio and improved manufacturing efficiency. YoY sales growth of 45% and operating profit growth of 86.3%.
M&A Activity · Asia
Torrent Pharmaceuticals →NCLT (National Company Law Tribunal) approved Torrent Pharma acquisition of JB Chemicals; merger scheme to take effect after Registrar of Companies filing
Restructuring · Asia
Samsung Biologics →Samsung Biologics unionized workers voted to leave the Samsung Group United Union and form an independent labor union, following months of work-to-rule campaigns and strikes over pay and working conditions.
Where this lands in our work
- Cross Border Expansion Executive Search →
Partnerships are usually the first structure a company builds before it hires locally.
- Executive Search: Asia →
Our Asia practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record